Cerebral amyloidosis: Amyloid subunits, mutants and phenotypes

Cellular and Molecular Life Sciences

Volumn 67, Issue 4, 2010, Pages 581-600

  Rostagno, A ^a   Holton, J L ^b   Lashley, T ^b   Revesz, T ^b   Ghiso, Jorge ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid plaques; Amyloid proteins; Cerebral amyloid angiopathy; Protein folding disorders

Indexed keywords

AMYLOID; CYSTATIN C; GELSOLIN; IMMUNOGLOBULIN; MUTANT PROTEIN; PREALBUMIN; PRESENILIN; PROTEIN SUBUNIT; TAU PROTEIN; AMYLOID BETA PROTEIN;

AMINO ACID SEQUENCE; AMYLOIDOSIS; CEREBRAL AMYLOIDOSIS; COGNITIVE DEFECT; DEMENTIA; EXTRAPYRAMIDAL SYNDROME; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; NERVE DEGENERATION; PATHOGENESIS; PHENOTYPE; PROTEIN FOLDING; REVIEW; STROKE; VASCULAR AMYLOIDOSIS; BRAIN; BRAIN DISEASE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PEDIGREE;

AMYLOID; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; BRAIN; BRAIN DISEASES; HUMANS; MUTATION; PEDIGREE; PROTEIN FOLDING;

EID: 75649127668     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-009-0182-4     Document Type: Review

References (159)

1. Dobson CM (2001) Protein folding and its links with human disease. Biochem Soc Symp 68:1-26
2. Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296:1991-1995
3. Lovestone S, McLoughlin DM (2002) Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosurg Psychiatry 2002:152-161
4. Temussi PA, Masino L, Pastore A (2003) From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J 22:355-361
5. LeVine H (1995) Thioflavine T interaction with amyloid b-sheet structures. Amyloid 2:1-6
6. Klunk WE, Jacob RF, Mason RP (1999) Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol 309:285-305
7. Ghiso J, Frangione B (2002) Amyloidosis and Alzheimer's disease. Adv Drug Delivery Rev 54:1539-1551
8. Farkas E, Luiten PGM (2001) Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64:575-611
9. Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 26:573-578
10. de la Torre JC (2004) Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 26:517-524
11. Gorelick PB (2004) Risk factors for vascular dementia and Alzheimer's disease. Stroke 35:2620-2627
12. Petty MA, Wettstein JG (2001) Elements of cerebral micro-vascular ischaemia. Brain Res Rev 36:23-34
13. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249
14. Kang I, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
15. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283:29615-29619
16. Iwatsubo T (2004) The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 14:379-383
17. Selkoe DJ, Wolfe MS (2007) Presenililn: running with scissors in the membrane. Cell 131:215-221
18. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ (1993) Beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 90:10836-10840
19. Kokjohn TA, Roher A (2009) Amyloid precursor protein transgenic mouse models and Alzheimr's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement 5:340-347
20. Roses A (1997) Genetic testing for Alzheimer disease. Practical and ethical issues. Arch Neurol 54:1226-1229
21. Roses A (1997) A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease. Neurogenetics 1:3-11
22. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68:613-618
23. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238
24. Selkoe D (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:23-31
25. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rost-agno A, Ghiso J (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 118:115-130
26. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of b-amyloid. Nat Genet 1:345-347
27. Cai XD, Golde TE, Younkin S (1993) Release of excess amyloid b protein from a mutant amyloid b protein precursor. Science 259:514-516
28. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the b-amyloid precursor protein in familial Alzheimer's disease increases b-protein production. Nature 360:672-674
29. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone C, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Fran-cescucci B, Spagnoli A, Cantù L, Del Favero E, Levy E, Salmona M, Tagliavini F (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323:1473-1477
30. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, Golde TE, Younkin S (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (APP717) mutants. Science 264:1336-1340
31. Wakutani Y, Watanabe K, Adachi Y, Wada-Isoe K, Urakami K, Ninomiya H, Saido TC, Hashimoto T, Iwatsubo T, Nakashima K (2004) Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 75:1039-1042
32. Levy E, Carman MD, Fernandez Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Frangione B (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124-1126
33. Bornebroek M, Haan J, Roos N (1999) Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of the variety in phenotypic expression. Amyloid 6:215-224
34. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Stürchler-Pierrat C, Bürki K, van Duinen SG, Maat-Schieman MLC, Staufenbiel M, Mathews PM, Jucker M (2004) Ab is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7:954-960
35. Maat-Schieman MLC, Yamaguchi H, Hegeman-Kleinn IM, Welling-Graafland C, Natté R, Roos RAC, van Duinen S (2004) Glial reactions and the clearance of amyloid b protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Acta Neuropathol 107:389-398
36. Maat-Schieman M, Yamaguchi H, van Duinen S, Natte R, Roos RA (2000) Age-related plaque morphology and C-terminal heterogeneity of amyloid b in Dutch-type hereditary cerebral hemorrhage with amyloidosis. Acta Neuropathol 99:409-419
37. Natte R, Maat-Schieman M, Haan J, Bornebroek M, Roos R, van Duinen S (2001) Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofi-brillary tangles. Ann Neurol 50:765-772
38. Castano EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B (1996) The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J Biol Chem 271:32185-32191
39. Prelli F, Levy E, van Duinen SG, Bots GT, Luyendijk W, Frangione B (1990) Expression of a normal and variant Alzheimer's b-protein gene in amyloid of hereditary cerebral hemorrhage, Dutch type: DNA and protein diagnostic assays. Biochem Biophys Res Commun 170:301-307
40. Nishitsuji K, Tomiyama T, Ishibashi K, Ito K, Teraoka R, Lambert MP, Klein WL, Mori H (2009) The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplas-mic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 174:957-969
41. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J (2000) Substitution at codon 22 of Alzheimer's Ab peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 275:27110-27116
42. Davis JB, van Nostrand WE (1996) Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Proc Natl Acad Sci USA 93:2996-3000
43. Viana RJ, Nunes AF, Castro RE, Ramalho RM, Meyerson J, Fossati S, Ghiso J, Rostagno A, Rodrigues CM (2009) Taur-oursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell Mol Life Sci 66:1094-1104
44. Solito R, Corti F, Fossati S, Mezhericher E, Donnini S, Ghiso J, Giachetti A, Rostagno A, Ziche M (2009) Dutch and Arctic mutant peptides of beta amyloid(1-40) differentially affect the FGF-2 pathway in brain endothelium. Exp Cell Res 315:385-395
45. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H (2008) A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63:377-387
46. Takuma H, Teraoka R, Mori H, Tomiyama T (2007) Amyloid b E22delta variant induces synapse alteration in mouse hippo-campal slices. Neuroreport 19:615-619
47. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4:887-893
48. Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'dahl S, Nemens E, White JA, Sadovnick AD, Ball MJ, Kaye JA, Warren A, McInnis MG, Antonarakis SE, Korenberg JR, Sharma V, Kukull WA, Larson EB, Heston LL, Martin GM, Bird TD, Schellenberg GD (1992) Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 51:998-1014
49. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, Hofman A, Van Broeckhoven C (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1:218-221
50. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow D (1997) Amyloid b-protein fibrillogenesis. Detection of a proto-fibrillar intermediate. J Biol Chem 272:22364-22372
51. van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW (2001) Pathogenic effects of D23N Iowa mutant amyloid b-protein. J Biol Chem 276:32860-32866
52. 692-[Gly) Alzheimer's disease. Biochem J 355:869-877
53. Grabowski TJ, Cho HS, Vonsattel JPG, Rebeck GW, Greenberg SM (2001) A novel APP mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 49:697-705
54. Zhang-Nunes SX, Maat-Schieman M, van Duinen S, Roos R, Frosch MP, Greenberg SM (2006) The cerebral b-amyloid angiopathies: hereditary and sporadic. Brain Pathol 16:30-39
55. Greenberg SM, Shin Y, Grabowski TJ, Cooper GE, Rebeck GW, Iglesias S, Chapon F, Tournier-Lasserve E, Baron JC (2003) Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology 60:1020-1022
56. Iglesias S, Chapon F, Baron JC (2000) Familial occipital calcifications, hemorrhagic strokes, leukoencephalopathy, dementia, and external carotid dysplasia. Neurology 55:1661-1667
57. Shin Y, Cho HS, Rebeck GW, Greenberg BD (2002) Vascular changes in Iowa-type hereditary cerebral amyloid angiopathy. Ann N Y Acad Sci 977:245-251
58. Shin Y, Cho HS, Fukumoto H, Shimizu T, Shirasawa T, Greenberg SM, Rebeck GW (2003) Abeta species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy. Acta Neuropathol 105:252-258
59. Tomidokoro Y, Rostagno A, Greenberg SM, Frangione B, Rebeck GW, Ghiso J (2004) Biochemical analysis of Ab amyloid deposits in the Iowa variant of Alzheimer's disease. Neurobiol Aging 25:38
60. Gabizon R, Telling G, Meiner Z, Halimi M, Kahana I, Prusiner SB (1996) Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Nat Med 2:59-64
61. Ando Y, Ando E, Ohlsson P-I, Olofsson A, Sandgren O, Suhr O, Terazaki H, Obayashi K, Lundgren E, Ando M, Negi A (1999) Analysis of transthyretin amyloid fibrils from vitreous samples in familial amyloidotic polyneuropathy (Val30Met). Amyloid 6:119-123
62. Thylén C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E (1993) Modification of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 12:743-748
63. Dwulet FE, Benson MD (1986) Characterization of a transthy-retin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 78:880-886
64. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, Harihara Y, Baba S, Kametani F, Ikeda S-I (2000) Cardiac amyloid in patients with familial amyloid polyneurop-athy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 274:702-706
65. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD (2003) Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 28:438-442
66. Tomidokoro Y, Lashley T, Rostagno A, Neubert TA, Bojsen-Moller M, Braendgaard H, Plant G, Holton J, Frangione B, Revesz T, Ghiso J (2005) Familial Danish dementia: co-existence of ADan and Ab amyloid subunits in the absence of compact plaques. J Biol Chem 280:36883-36894
67. Frangione B, Wisniewski T, Tagliavini F, Bugiani O, Ghiso J (1993) Alzheimer's disseasse and Dutch variant: opposing faces of a single coin. In: Corain B, Iqbal K, Nicolini B, Winblad B, Wisniewski HM, Zatta P (eds) Alzheimer's disease: advances in clinical and basic research. Wiley, Chichester, pp 387-396
68. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 147:238-244
69. Davis JB, Cribbs DH, Cotman CW, van Nostrand WE (1999) Pathogenic amyloid beta-protein induces apoptosis in cultured human cerebrovascular smooth muscle. Amyloid 6:157-164
70. Obici L, Demarchi A, de Rosa G, Bellotti V, Marciano S, Donadei S, Arbustini E, Palladini G, Diegoli M, Genovese E, Ferrari G, Coverlizza S, Merlini G (2005) A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 58:639-644
71. Cam J, Meyerson J, Mezhericher E, Frangione B, Ghiso J, Rostagno A (2007) Differential apoptotic response of primary human cerebral endothelial cells to oligomeric assemblies of amyloid beta genetic variants. In: Fisher A, Hanin I, Poewe W, Windisch M (eds) New trends in Alzheimer and Parkinson disorders. Medimond International Proceedings, Bologna, Italy, pp 141-146
72. Fossati S, Cam J, Meyerson J, Mezhericher E, Romero IA, Couraud P-O, Weksler B, Ghiso J, Rostagno A (2009) Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-b variants in cells composing the cerebral vessel walls. FASEB J [Epub ahead of print]
73. Rossi G, Giaccone G, Maletta R, Morbin M, Capobianco R, Mangieri M, Giovagnoli AR, Bizzi A, Tomaino C, Perri M, Di Natale M, Tagliavini F, Bugiani O, Bruni AC (2004) A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology 63:910-912
74. Carter DA, Desmarais E, Bellis M, Campion D, Clerget-Darpoux F, Brice A, Agid Y, Jaillard-Serradt A, Mallet J (1992) More missense in amyloid gene. Nat Genet 2:255-256
75. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I (2004) Familial Alzheimer disease associated with A713T mutation in APP. Neuroreport 370:241-243
76. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
77. Hori Y, Hashimoto T, Wakutani Y, Urakami K, Nakashima K, Condron MM, Tsubuki S, Saido T, Teplow D, Iwatsubo T (2007) The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Ab fibril formation without increasing protofibril formation. J Biol Chem 282:4916-4923
78. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J (2003) Early onset familial Alzheimer's disease. Mutation frequency in 31 families. Neurology 60:235-239
79. Brouwers N, Sleegers K, Van Broeckhoven C (2008) Molecular genetics of Alzheimer's disease: an update. Ann Med 40:562-583
80. Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R (2004) Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J Biol Chem 279:39010-39016
81. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley Y-HF, Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973-977
82. Rosenberg RN (2000) The molecular and genetic basis of AD: the end of the beginning. Neurology 54:2045-2054
83. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A, Van Broeckhoven C (1998) Estimation of the genetic contribution of presenilin-1 and-2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 7:43-51
84. Finckh U, Müller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, Binetti G, Alberici A, Hock C, Nitsch RM, Gal A (2000) High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 66:110-117
85. Lleo A, Blesa R, Gendre J, Castellv́i M, Pastor P, Queralt R, Oliva R (2001) A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease. Neurology 57:1926-1928 (Pubitemid 33096714)
86. Ezquerra M, Lleo A, Castellvy M, Queralt R, Santacruz P, Pastor P, Molinuevo JL, Blesa R, Oliva R (2003) A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol 60:1149-1151
87. Marcon G, Di Fede G, Giaccone G, Rossi G, Giovagnoli AR, Maccagnano E, Tagliavini F (2009) A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. J Alzhei-mers Dis 16:509-511
88. Lippa CF, Swearer JM, Kane KJ, Nochlin D, Bird TD, Ghetti B, Nee LE, St George-Hyslop P, Pollen DA, Drachman DA (2000) Familial Alzheimer's disease: site of mutation influences clinical phenotyp. Ann Neurol 48:376-379
89. Finckh U, Alberici A, Antoniazzi M, Benussi L, Fedi V, Giannini C, Gal A, Nitsch RM, Binetti G (2000) Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology 54:2006-2008
90. Bird TD, Levy-Lahad E, Poorkaj P, Sharma V, Nemens E, Lahad A, Lampe TH, Schellenberg GD (1996) Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. Ann Neurol 40:932-936
91. Steiner H, Revesz T, Neumann M, Romig H, Grim MG, Pesold B, Kretzschmar HA, Hardy J, Holton J, Baumeister R, Houlden H, Haass C (2001) A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. J Biol Chem 276:7233-7239
92. Gudmundsson G, Hallgrimsson J, Jonasson T, Bjarnason O (1972) Hereditary cerebral hemorrhage with amyloidosis. Brain 95:387-404
93. Levy E, Lopez-Otin C, Ghiso J, Geltner D, Frangione B (1989) Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. J Exp Med 169:1771-1778
94. Ghiso J, Jensson O, Frangione B (1986) Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). Proc Natl Acad Sci USA 83:2974-2978 (Pubitemid 16041784)
95. Ghiso J, Pons-Estel B, Frangione B (1986) Hereditary cerebral amyloid angiopathy: the amyloid contain a protein which is a variant of cystatin C, an inhibitor of lysosomal cysteine proteases. Biochem Biophys Res Commun 136:548-554
96. Levy E, Jascolski M, Grubb A (2006) The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 16:60-70
97. Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A, Abrahamson M, Jaskolski M (2001) Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol 8:316-320
98. Janowski R, Kozak M, Abrahamson M, Grubb A, Jaskolski M (2005) 3D Domain-swapped human cystatin C with amyloid like intermolecular-sheets. Struct Funct Bioinform 61:570-578
99. Janowski R, Abrahamson M, Grubb A, Jaskolski M (2004) Domain swapping in N-truncated cystatin C. J Mol Biol 341:151-160
100. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton J (2003) Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62:885-898
101. Kiuru S (1998) Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 5:55-66
102. Haltia M, Ghiso J, Prelli F, Gallo G, Kiuru S, Somer H, Palo J, Frangione B (1990) Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin. Am J Pathol 136:223-228
103. Haltia M, Prelli F, Ghiso J, Kiuru S, Somer H, Palo J, Frangione B (1990) Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsollin, an actin-binding protein. Biochem Biophys Res Commun 176:927-932 (Pubitemid 20113270)
104. Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B (1990) Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 172:1865-1867
105. Ghiso J, Haltia M, Prelli F, Novello J, Frangione B (1990) Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type. Biochem J 272:827-830
106. Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H (1996) Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology 47:1562-1567
107. Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, Wisniewski T (1996) Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol 148:351-354
108. Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, Gali M, Estes M, Gambetti P (1997) Transthyretin amyloidos: a new mutation associated with dementia. Ann Neurol 41:307-313
109. Frangione B, Vidal R, Rostagno A, Ghiso J (2000) Familial cerebral amyloid angiopathies and dementia. Alzheimer Dis Assoc Disord 14:S25-S30
110. Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M (2001) Familial amyloidotic polyneu-ropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 51:476-480
111. Schröder R, Deckert M, Linke RP (2009) Novel isolated cerebral ALlambda amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical monoclonal plasma cell proliferation, and terminal systemic gammopathy. J Neuropathol Exp Neurol 68:286-299
112. Vidal R, Ghiso J, Gallo G, Cohen M, Gambetti PL, Frangione B (1992) Amyloidoma of the CNS. II. Immunohistochemical and biochemical study. Neurology 42:2024-2028
113. Fischer B, Palkovic S, Rickert C, Weckesser M, Wassmann H (2007) Cerebral AL lambda-amyloidoma: clinical and pathomorphological characteristics. Review of the literature and of a patient. Amyloid 14:11-19
114. Simoens WA, Van den Hauwe L, Van Hedent E, Warson F, Demaeseneer R, Williams D, De Schepper AMA (2000) Amy-loidoma of the skull base. Am J Neuroradiol 21:1559-1562
115. Vorster SJ, Lee JH, Ruggieri P (1998) Amyloidoma of the Gasserian ganglion. Am J Neuroradiol 19:1853-1855
116. McKechnie S, Yang F, Harper CG, McGee-Collett M, Henderson CJA, Liepnieks JJ, Yazaki M, Benson MD, McLeod JG (2003) Amyloidoma of a spinal root. Neurology 61:834-836
117. Mulleman D, Flipo RM, Assaker R (2004) Primary amyloidoma of the axis and acute spinal cord compression: a case report. Eur Spine J 13:244-248
118. Consales A, Roncaroli F, Salvi F, Poppi M (2003) Amyloidoma of the brachial plexus. Surg Neurol 59:418-423
119. Rodriguez FJ, Gamez JD, Vrana JA, Theis JD, Giannini C, Scheithauer BW, Parisi JE, Lucchinetti CF, Pendlebury WW, Bergen H Rr, Dogan A (2008) Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest 88:1024-1037
120. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962-10966
121. Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B, Bugiani O, Giaccone G, Prelli F, Goedert M, Dlouhy SR, Tagliavini F (1996) Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci USA 93:744-748
122. Paulick MG, Bertozzi CR (2008) The glycosylpho-sphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 47:6991-7000
123. Rostagno A, Tomidokoro Y, Lashley T, Ng D, Plant G, Holton J, Frangione B, Revesz T, Ghiso J (2005) Chromosome 13 dementias. Cell Mol Life Sci 62:1814-1825
124. Ghiso J, Vidal R, Rostagno A, Miravalle L, Holton J, Revesz T, Plant G, Frangione B (2000) Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. In: Growdon J, Wurtman R, Corkin S, Nitsch R (eds) Molecular basis of dementia, vol 927. New York Academy of Sciences, New York, pp 84-92
125. Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L (2005) The familial dementia BRI2 gene binds the Alzheimer's gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem 280:28912-28916
126. Matsuda S, Giliberto L, Matsuda T, Mc-Gowan E, D'Adamio L (2008) BRI2 inhibits amyloid beta peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci 28:8668-8676
127. Fotinopoulou A, Tsachaki M, Vlavaki M, Poulopoulos A, Rostagno A, Frangione B, Ghiso J, Efthimiopoulos S (2005) BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem 280:30768-30772
128. Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin S, Graff-Radford N, Dickson D, Rosenberry T, Golde TE (2008) BRI2 (Itm2b) inhibits Ab deposition in vivo. J Neurosci 28:6030-6036
129. Worster-Drought C, Hill T, McMenemey W (1933) Familial presenile dementia with spastic paralysis. J Neurol Psychopathol 14:27-34
130. Ghiso J, Holton J, Miravalle L, Calero M, Lashley T, Vidal R, Houlden H, Wood N, Neubert TA, Rostagno A, Plant G, Revesz T, Frangione B (2001) Systemic amyloid deposits in Familial British Dementia. J Biol Chem 276:43909-43914
131. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J (1999) A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399:776-781
132. Vidal R, Ghiso J, Revesz T, Rostagno A, Kim E, Holton J, Bek T, Bojsen-Moller M, Braendgaard H, Plant G, Frangione B (2000) A decamer duplication in the 3' region of the BRI gene originates a new amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA 97:4920-4925
133. Ghiso J, Rostagno A, Tomidokoro Y, Lashley T, Bojsen-Moller M, Braendgaard H, Plant G, Holton J, Lal R, Revesz T, Fran-gione B (2006) Genetic alterations of the BRI2 gene: familial British and Danish dementias. Brain Pathol 16:71-79
134. Holton J, Ghiso J, Lashley T, Rostagno A, Guerin C, Gibb G, Houlden H, Ayling H, Martinian L, Anderton B, Wood N, Vidal R, Plant G, Frangione B, Revesz T (2001) Regional distribution of fibrillar and non-fibrillar ABri deposition and its association with neurofibrillary degeneration in Familial British Dementia. Am J Pathol 158:515-526
135. Holton J, Lashley T, Ghiso J, Braendgaard H, Vidal R, Guerin C, Gibb G, Hanger DP, Rostagno A, Anderton B, Strand C, Ayling H, Plant G, Frangione B, Bojsen-Moller M, Revesz T (2002) Familial Danish Dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol 61:254-267
136. Saido T, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawa-shima S (1995) Dominant and differential deposition of distinct b-amyloid peptide species, AbN3(pE), in senile plaques. Neuron 14:457-466
137. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK (1997) Heterogeneity of water-soluble amyloid b-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 409:411-416
138. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G (2002) Pyroglutamate-modified amyloid b-peptides-AbN3(pE)-strongly affect cultured neuron and astrocyte survival. J Neu-rochem 82:1480-1489
139. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Böhm G, Demuth H-U (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45:12394-12399
140. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD (2005) Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12:1-4
141. Kirschner DA, Abraham C, Selkoe DJ (1986) X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-b conformation. Proc Natl Acad Sci USA 83:503-507
142. Westermark P, Benson MD, Buxbaum J, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD (2007) A primer of amyloid nomenclature. Amyloid 14:179-183
143. Mandelkow E, Song YH, Schweers O, Marx A, Mandelkow EM (1995) On the structure of microtubules, tau, and paired helical filaments. Neurobiol Aging 16:347-354
144. Goedert M, Klug A, Crowther RA (2006) Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis 9:195-207
145. Delacourte A, Buee L (2000) Tau pathology: a marker of neu-rodegenerative disorders. Curr Opin Neurol 13:371-376
146. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neu-rodegenerative disorders. Brain Res Rev 33:95-130
147. Caughey B, Lansbury PTJ (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the inocent bystanders. Annu Rev Neurosci 26:267-298
148. Walsh DM, Selkoe DJ (2007) A beta oligomers-a decade of discovery. J Neurochem 101:1172-1184
149. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegenera-tion in Alzheimer's disease. Ann Neurol 46:860-866
150. Lue L-F, Kuo Y-M, Roher A, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel R, Rogers J (1999) Soluble amyloid beta concentration is a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862
151. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch C, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422
152. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogene-sis. Science 300:486-489
153. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat Rev Mol Cell Biol 8:101-112
154. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089-1102
155. Conway KA, Harper JD, Lansbury PT (2000) Fibrils formed in vitro from a-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39:2552-2563
156. Conway KA, Harper JD, Lansbury PTJ (1998) Accelerated in vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-1320
157. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-576
158. Marchut AJ, Hall CK (2006) Spontaneous formation of annular structures observed in molecular dynamics simulations of polyglutamine peptides. Comput Biol Chem 30:215-218
159. Quist A, Doudevski I, Lin H, Azimova D, Ng D, Frangione B, Kagan B, Ghiso J, Lal R (2005) Amyloids form membrane pores: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 102:10427-10432